{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:42:15Z","timestamp":1793378535900,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clgc.2025.102300","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T23:22:55Z","timestamp":1736378575000},"page":"102300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinically Meaningful Upstaging and Upgrading in Favorable Intermediate-Risk Radical Prostatectomy Patients"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2613-2306","authenticated-orcid":false,"given":"Mattia","family":"Longoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8585-3701","authenticated-orcid":false,"given":"Francesco","family":"Di Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3057-3805","authenticated-orcid":false,"given":"Natali","family":"Rodriguez Pe\u00f1aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1907-3982","authenticated-orcid":false,"given":"Fabian","family":"Falkenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marmiroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh Chi","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan A.","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1597-9595","authenticated-orcid":false,"given":"Stefano","family":"Puliatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavio","family":"de Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K.H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2025.102300_bib0001","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euf.2017.05.011","article-title":"Risk of upgrading and upstaging among 10 000 patients with Gleason 3 + 4 favorable intermediate-risk prostate cancer","volume":"5","author":"Yang","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.clgc.2025.102300_bib0002","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00345-021-03816-0","article-title":"The impact of race\/ethnicity on upstaging and\/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy","volume":"40","author":"Nocera","year":"2022","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102300_bib0003","doi-asserted-by":"crossref","first-page":"590","DOI":"10.23736\/S2724-6051.21.04314-7","article-title":"Improving the stratification of intermediate risk prostate cancer","volume":"74","author":"Nocera","year":"2022","journal-title":"Minerva Urol Nephrol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102300_bib0004","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.eururo.2016.08.043","article-title":"Adverse disease features in Gleason score 3 + 4 \u201cfavorable intermediate-risk\u201d prostate cancer: implications for active surveillance","volume":"72","author":"Morlacco","year":"2017","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.clgc.2025.102300_bib0005","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00345-020-03485-5","article-title":"No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favorable intermediate-risk prostate cancer: implications for active surveillance","volume":"39","author":"Herkommer","year":"2021","journal-title":"World J Urol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102300_bib0006","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s11255-024-04019-3","article-title":"Tumor upgrading among very favorable intermediate-risk prostate cancer patients treated with robot-assisted radical prostatectomy: how can it impact the clinical course?","volume":"56","author":"Porcaro","year":"2024","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102300_bib0007","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1007\/s00345-021-03717-2","article-title":"Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance","volume":"39","author":"Meissner","year":"2021","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102300_bib0008","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.juro.2018.04.058","article-title":"Subtyping the risk of intermediate risk prostate cancer for active surveillance based on adverse pathology at radical prostatectomy","volume":"200","author":"Patel","year":"2018","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102300_bib0009","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.clgc.2025.102300_bib0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2025.102300_bib0011","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00345-022-04228-4","article-title":"Prostate cancer mortality rates in low- and favorable intermediate-risk active surveillance patients: a population-based competing risks analysis","volume":"41","author":"Sayyid","year":"2023","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2025.102300_bib0012","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.clgc.2023.04.009","article-title":"Intermediate grade prostate cancer and risk for adverse pathology radical prostatectomy: implications for partial gland ablation case selection","volume":"21","author":"Stangl-Kremser","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2025.102300_bib0013","article-title":"The impact of prostate cancer upgrading and upstaging on biochemical recurrence and cancer-specific survival","volume":"56","author":"Bakavi\u010dius","year":"2020","journal-title":"Medicina (Lithuania)"},{"issue":"10","key":"10.1016\/j.clgc.2025.102300_bib0014","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1007\/s11255-022-03250-0","article-title":"Adverse upgrading and\/or upstaging in contemporary low-risk prostate cancer patients","volume":"54","author":"Flammia","year":"2022","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102300_bib0015","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/bju.14418","article-title":"Effects of pathologic upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer HHS Public Access","volume":"122","author":"Kovac","year":"2018","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.clgc.2025.102300_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.10.005","article-title":"Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy","volume":"40","author":"Brooks","year":"2022","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"6","key":"10.1016\/j.clgc.2025.102300_bib0017","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1016\/j.clgc.2023.06.001","article-title":"Novel approaches in the systemic management of high-risk prostate cancer","volume":"21","author":"G\u00f3mez-Aparicio","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102300_bib0018","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2024.07.009","article-title":"Re: long-term prostate cancer-specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer","volume":"87","author":"Montorsi","year":"2025","journal-title":"Eur Urol"},{"issue":"35","key":"10.1016\/j.clgc.2025.102300_bib0019","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1200\/JCO.24.01067","article-title":"Improving assessment of radiorecurrent prostate cancer: implications for salvage reirradiation","volume":"42","author":"Montorsi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102300_bib0020","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2023.09.024","article-title":"Long-term prostate cancer\u2013specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer","volume":"85","author":"Herlemann","year":"2024","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102300_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.08.030","article-title":"Stratifying patients with intermediate-risk prostate cancer: validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications","volume":"39","author":"Diamand","year":"2021","journal-title":"Urol Oncol: seminars and original investigations"},{"issue":"19","key":"10.1016\/j.clgc.2025.102300_bib0022","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2025.102300_bib0023","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41585-019-0212-4","article-title":"Multiparametric MRI for prostate cancer diagnosis: current status and future directions","volume":"17","author":"Stabile","year":"2020","journal-title":"Nat Rev Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:36:31Z","timestamp":1741696591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1558767325000023"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102300","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically Meaningful Upstaging and Upgrading in Favorable Intermediate-Risk Radical Prostatectomy Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102300"}}